394 related articles for article (PubMed ID: 20016367)
1. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
2. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a potent and selective aurora kinase inhibitor.
Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
[TBL] [Abstract][Full Text] [Related]
4. Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ; Mathijssen RH; Verweij J; de Wit R; de Jonge MJ
Expert Opin Investig Drugs; 2012 Mar; 21(3):383-93. PubMed ID: 22242557
[TBL] [Abstract][Full Text] [Related]
5. AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer.
Kimura S
Curr Opin Investig Drugs; 2010 Dec; 11(12):1442-9. PubMed ID: 21154126
[TBL] [Abstract][Full Text] [Related]
6. Development and biological evaluation of a novel aurora A kinase inhibitor.
Sardon T; Cottin T; Xu J; Giannis A; Vernos I
Chembiochem; 2009 Feb; 10(3):464-78. PubMed ID: 19199284
[TBL] [Abstract][Full Text] [Related]
7. Aurora kinase inhibitors.
Kitzen JJ; de Jonge MJ; Verweij J
Crit Rev Oncol Hematol; 2010 Feb; 73(2):99-110. PubMed ID: 19369091
[TBL] [Abstract][Full Text] [Related]
8. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
9. Is there a future for Aurora kinase inhibitors for anticancer therapy?
Carpinelli P; Moll J
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):533-42. PubMed ID: 19562649
[TBL] [Abstract][Full Text] [Related]
10. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
[TBL] [Abstract][Full Text] [Related]
11. Aurora A: target invalidated?
Cochran AG
Chem Biol; 2008 Jun; 15(6):525-6. PubMed ID: 18559262
[TBL] [Abstract][Full Text] [Related]
12. Mitotic drivers--inhibitors of the Aurora B Kinase.
Keen N; Taylor S
Cancer Metastasis Rev; 2009 Jun; 28(1-2):185-95. PubMed ID: 19189202
[TBL] [Abstract][Full Text] [Related]
13. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
[TBL] [Abstract][Full Text] [Related]
14. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.
Evans RP; Naber C; Steffler T; Checkland T; Maxwell CA; Keats JJ; Belch AR; Pilarski LM; Lai R; Reiman T
Br J Haematol; 2008 Feb; 140(3):295-302. PubMed ID: 18076711
[TBL] [Abstract][Full Text] [Related]
15. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
[TBL] [Abstract][Full Text] [Related]
17. Aurora kinase inhibitors: a new class of targeted drugs in cancer.
Gautschi O; Mack PC; Davies AM; Lara PN; Gandara DR
Clin Lung Cancer; 2006 Sep; 8(2):93-8. PubMed ID: 17026809
[TBL] [Abstract][Full Text] [Related]
18. Aurora A and B kinases as targets for cancer: will they be selective for tumors?
Matthews N; Visintin C; Hartzoulakis B; Jarvis A; Selwood DL
Expert Rev Anticancer Ther; 2006 Jan; 6(1):109-20. PubMed ID: 16375648
[TBL] [Abstract][Full Text] [Related]
19. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
20. Aurora kinases as targets for cancer therapy.
Mountzios G; Terpos E; Dimopoulos MA
Cancer Treat Rev; 2008 Apr; 34(2):175-82. PubMed ID: 18023292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
